Market News / Story
Outlook Therapeutics, Inc. (OTLK) Features New CFO Amid LYTENAVA Launch Plans
·
Outlook Therapeutics highlighted newly appointed CFO Kevin Lundquist in a Virtual Investor segment as the company moves toward the U.S. commercial launch of FDA‑approved LYTENAVA for wet AMD. Material Details #DetailAI Analyst View1New CFO Kevin Lundquist featuredC-suite change can signal strategic priorities and execution focus heading into commercialization.2FDA-approved LYTENAVA notedRegulatory approval de-risks the asset; next step is converting approval into…